Eli Lilly and Company (NYSE:LLY) Stock Price Down 1% – Should You Sell?

Eli Lilly and Company (NYSE:LLY) shares were down 1% during trading on Thursday . The stock traded as low as $890.70 and last traded at $894.54. Approximately 504,112 shares changed hands during trading, a decline of 83% from the average daily volume of 2,956,188 shares. The stock had previously closed at $903.25.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on LLY shares. Citigroup raised their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday. Truist Financial boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,013.41.

Eli Lilly and Company Stock Performance

The stock has a market cap of $848.27 billion, a P/E ratio of 109.92, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock’s 50 day simple moving average is $919.74 and its two-hundred day simple moving average is $861.75.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, research analysts forecast that Eli Lilly and Company will post 14.05 EPS for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently bought and sold shares of the company. OneAscent Wealth Management LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $359,000. Webster Bank N. A. increased its position in shares of Eli Lilly and Company by 2.9% in the first quarter. Webster Bank N. A. now owns 1,982 shares of the company’s stock valued at $1,542,000 after acquiring an additional 56 shares during the last quarter. Norris Perne & French LLP MI acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $318,000. Total Investment Management Inc. acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $203,000. Finally, WD Rutherford LLC bought a new position in Eli Lilly and Company in the first quarter valued at approximately $187,000. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.